Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

May 2021

SALT LAKE CITY, May 18, 2021 -- Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the presentation of data from a systematic literature review characterizing the

Read more